Real-world utility of ctDNA NGS to identify matched targeted therapy
Liquid biopsy for plasma circulating tumour DNA (ctDNA) next generation sequencing (NGS) is a rapidly evolving science. Plasma ctDNA assays are now commercially available, and are increasingly adopted in the community with a paucity of evidence-based guidance on timing and value of this test. Sabari et al. sought to determine the feasibility and utility of plasma ctDNA NGS to identify matched targeted therapy in a real-world clinical setting. At two sites, a total of 27 patients with metastatic adenocarcinoma of the lung and unknown driver mutation or unknown resistance mechanism were enrolled.
Plasma ctDNA NGS identified a variety of oncogenic drivers with a short median turnaround time of 6 days (vs. 21 days for tissue NGS; p < 0.0001) and matched them to targeted therapy in 14 % of cases. Plasma ctDNA was more frequently detected at diagnosis of metastatic disease or at progression. In patients on therapy, ctDNA detection rate was 46 %, and in those off therapy, 73 % (odds ratio, 0.31; p = 0.02). The plasma NGS concordance rate with tissue NGS regarding driver mutations was 96 %; for tissue NGS concordance with plasma NGS, this was 60 %. The authors concluded that a positive finding in plasma is highly specific and can immediately guide treatment, whereas a negative finding might still require tissue biopsy.
Sabari JK et al., Liquid biopsy in the clinic: a prospective study of plasma ctDNA NGS in patients with advanced NSCLCs to matched targeted therapy. ASCO 2017, abstract 11536
More posts
Anti-angiogenic and immunotherapeutic approaches in mesothelioma
Malignant pleural mesothelioma (MPM) is a rare tumour that is often diagnosed at an advanced stage. Limited efficacy of the available therapies contributes to the generally poor prognosis for MPM patients. Since 2003, the only approved regimen for MPM treatment has been chemotherapy with pemetrexed and cisplatin, with median survival of approximately 12 months.
Interview: Lung cancer in China: hurdles and progress
Lung cancer is a considerable issue in China. Every year, we have 700,000 new cases. There is a need to perform clinical trials and to launch innovative drugs. With regard to the introduction of targeted therapies, China lags 3 to 4 years behind when compared to the western countries. Two months ago, the EGFR TKI afatinib was launched, offering Chinese patients with EGFR-mutant lung cancer an effective treatment option.
Real-world utility of ctDNA NGS to identify matched targeted therapy
Liquid biopsy for plasma circulating tumour DNA (ctDNA) next generation sequencing (NGS) is a rapidly evolving science. Plasma ctDNA assays are now commercially available, and are increasingly adopted in the community with a paucity of evidence-based guidance on timing and value of this test. Sabari et al. sought to determine the feasibility and utility of plasma ctDNA NGS to identify matched targeted therapy in a real-world clinical setting.
Further defining the optimal use of immune checkpoint inhibitors
As the anti-PD-1 antibody nivolumab is known to induce deep and durable responses in a subset of lung cancer patients, this agent was investigated in the neoadjuvant setting, which is an area of unmet need. There have been no advances in systemic treatment of resectable lung cancer since 2004. Chaft et al. hypothesised that neoadjuvant nivolumab treatment might induce immunity against micrometastases.
Established targeted agents taking root in the HER2-positive setting
HER2 aberrations in lung cancer are being increasingly identified due to the use of sensitive testing procedures, such as multiplexed testing and next-generation sequencing. Mutations of the HER2 gene need to be distinguished from HER2 amplifications and HER2 protein overexpression. In contrast to breast and gastric cancer, HER2 overexpression in NSCLC does not always occur with HER2 amplification, while amplifications and HER2 mutations are generally mutually exclusive.
Diagnostics of EGFR-mutant disease: biomarkers with significant clinical implications
The clinical relevance of additional genetic alterations in advanced EGFR-mutant NSCLC is not clear. Blakely et al. hypothesised that co-occurring genomic alterations in cancer-related genes can cooperate with the mutant EGFR to drive de-novo resistance to EGFR TKI treatments. The investigators performed targeted exome sequencing of plasma cell-free DNA (cfDNA) in 86 samples collected from 81 patients with known clinical history.
